Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Edwards LifesciencesWBO:EWLS +0.13%96 3-Year EPS without NRI Growth Rate is 1.10% as of Jun. 2026, which is 92% below its 10-year median of 13.70. GuruFocus rates WBO:EWLS with a GF Score™ of 96/100 and a GF Value™ of €81.79 (Fairly Valued). The stock has 5 warning signs investors should review. Among 661 Medical Devices & Instruments companies, Edwards Lifesciences ranks worse than 60.06% on this metric.
During the past 12 months, Edwards Lifesciences's average EPS without NRI Growth Rate was 9.30% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 1.10% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 5.50% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 12.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Edwards Lifesciences was 31.30% per year. The lowest was 1.10% per year. And the median was 13.70% per year.
Edwards Lifesciences (WBO:EWLS) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Edwards Lifesciences 3-Year EPS without NRI Growth Rate Related Terms
WBO:EWLS vs BSX, DXCM, GEHC: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, Edwards Lifesciences's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edwards Lifesciences 3-Year EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Edwards Lifesciences's 3-Year EPS without NRI Growth Rate falls into.
Edwards Lifesciences 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 1.10% mean?
Edwards Lifesciences (WBO:EWLS) has a 3-Year EPS without NRI Growth Rate of 1.10% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Edwards Lifesciences and its competitors. This is 92% below median its historical median of 13.70. Over the past decade, Edwards Lifesciences' 3-Year EPS without NRI Growth Rate has ranged from 1.10 to 31.30. According to the industry distribution chart, Edwards Lifesciences ranks #397 out of 661 companies in the Medical Devices & Instruments industry, placing it in the top 60.1%.
Is Edwards Lifesciences' 3-Year EPS without NRI Growth Rate too high?
Edwards Lifesciences' current 3-Year EPS without NRI Growth Rate of 1.10% is 92% below median its 10-year median of 13.70. Over the past 10 years, this metric has ranged from a low of 1.10 to a high of 31.30. The Medical Devices & Instruments industry median 3-Year EPS without NRI Growth Rate is 8.00. Edwards Lifesciences' value of 1.10% is 86.3% below this industry median. Based on the distribution chart, Edwards Lifesciences ranks #397 out of 661 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Edwards Lifesciences has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' 3-Year EPS without NRI Growth Rate compare to BSX and DXCM?
According to the Medical Devices & Instruments industry distribution chart, Edwards Lifesciences ranks #397 out of 661 companies for 3-Year EPS without NRI Growth Rate. This places Edwards Lifesciences in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 8.00. Edwards Lifesciences' value of 1.10% is 86.3% below this benchmark. Historically, Edwards Lifesciences' own 3-Year EPS without NRI Growth Rate has ranged from 1.10 to 31.30 over the past decade. While the company's 10-year median is 13.70 vs. the industry median of 8.00, Edwards Lifesciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EPS without NRI Growth Rate among Medical Devices & Instruments companies is 8.00, based on 661 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edwards Lifesciences's current 3-Year EPS without NRI Growth Rate of 1.10% is 86.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Edwards Lifesciences and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EPS without NRI Growth Rate is 8.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edwards Lifesciences's current 3-Year EPS without NRI Growth Rate is 1.10%, which is 92% below median its own 10-year median of 13.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Edwards Lifesciences (WBO:EWLS) is currently considered Fairly Valued. The stock's GF Value™ is €81.79, compared to a current price of €74.42 — trading 9% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 1.10%, which is 92% below median its 10-year median of 13.70 and 86.3% below the Medical Devices & Instruments industry median of 8.00. Edwards Lifesciences' overall GF Score™ is 96/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Edwards Lifesciences (WBO:EWLS), the current 3-Year EPS without NRI Growth Rate is 1.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edwards Lifesciences (WBO:EWLS) Overvalued in 2026?
Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued.
The current stock price of €74.42 is trading 9% below its estimated GF Value™ of €81.79.
GuruFocus considers Edwards Lifesciences to be Fairly Valued.
Key valuation signals for WBO:EWLS:
3-Year EPS without NRI Growth Rate: 1.10% (92% below median its 10-year median of 13.70)
GF Value™: €81.79 vs. price of €74.42 (9% below fair value)
Industry Position: 86.3% below the Medical Devices & Instruments median (#397 of 661)
No single metric tells the full story. See the WBO:EWLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
96GF Score
Get the complete analysis for WBO:EWLS
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:EWLS has been successfully added to your 
